Novo Nordisk plugs more than $1B into upgrade of Brazilian manufacturing operations for injectable drugs, including GLP-1s
Looking to grow production in Latin America’s biggest country, Novo Nordisk is charting a $1.09 billion expansion at its manufacturing plant in Brazil. The investment will “significantly” bolster the facility’s capacity to crank out a variety of injectables, including GLP-1 medicines like Ozempic and Wegovy, Novo said in an announcement.
Looking to grow production in Latin America’s biggest country, Novo Nordisk is charting a $1.09 billion expansion at its manufacturing plant in Brazil. The investment will “significantly” bolster the facility’s capacity to crank out a variety of injectables, including GLP-1 medicines like Ozempic and Wegovy, Novo said in an announcement.
